Takeda Pharmaceutical Company Limited and Nycomed jointly announced yesterday that Takeda has reached an agreement with the shareholders of Nycomed in which Takeda will acquire the Zurich company for $13.7 billion on a cash-free, debt-free basis. The acquisition excludes Nycomed’s U.S. dermatology business. This transformational transaction is a strategic fit with Takeda’s sustainable growth strategy of gaining an immediate strong presence in the high0growth emerging markets by using Nycomed’s strength in a geographically wide range of markets and its diverse talent base. If you are interested in more details about this transaction, check out our deal profile below.
– Implied Enterprise Value ($mm) $13,700
– LTM Sales ($mm) $4,300 – EV/Sales 3.2x
– LTM EBITDA ($mm) $1,217 – EV/EBITDA 11.3x